Int J Arrhythm.  2024 Jun;25(2):10. 10.1186/s42444-024-00117-6.

Role of anticoagulation with apixaban in left‑sided atrial tachycardias

Affiliations
  • 1Department of Medicine, University Hospital Coventry & Warwickshire, Coventry, UK
  • 2Department of Cardiology, Gomal Medical College, Dera Ismail Khan, Pakistan
  • 3Department of Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan
  • 4Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
  • 5Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
  • 6Department of Cardiology, Abbas Institute of Medical Sciences, Muzaffarabad, Pakistan
  • 7Department of Cardiovascular Medicine, Cardiovascular Analytics Group, Islamabad, Pakistan

Abstract

Background
Atrial tachycardia poses challenges in patient management due to the associated risks of stroke and systemic embolism. While anticoagulation is recommended in atrial fibrillation (AF), its role in atrial tachycardia remains less defined. This prospective study aimed to evaluate the efficacy and safety of apixaban, a direct oral anticoagulant, in individuals diagnosed with left-sided atrial tachycardias.
Methods
Patients diagnosed with left-sided atrial tachycardia (n = 439) were observed over 3 years. Baseline characteristics, medication regimens, and clinical outcomes were assessed. Apixaban-treated individuals (n = 213) received standard or reduced dosages, while the control group (n = 226) received standard care. Primary outcomes included stroke, systemic embolism, bleeding, and mortality rates.
Results
Baseline characteristics were comparable between groups. The apixaban cohort showed a lower incidence of stroke (7.0% vs. 9.3%, p = 0.027) and decreased all-cause mortality (11.7% vs. 12.8%, p = 0.012) compared to controls. No significant differences were found in major bleeding or systemic embolization between groups.
Conclusion
Apixaban demonstrated a potential benefit in reducing stroke and mortality rates in patients with leftsided atrial tachycardia. While requiring further validation, these findings suggest a potential role for apixaban in anticoagulation strategies for atrial tachycardia management.

Keyword

Atrial tachycardia; Apixaban; Anticoagulation; Stroke prevention; Clinical outcomes
Full Text Links
  • IJA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr